BCL2 and B-cell chronic lymphocytic leukemia: Several treatments available for CLL exert a long-term control of the disease in the majority of CLL patients, as novel tyrosine kinase inhibitors and the B-cell lymphoma 2 (BCL2) inhibitor ABT-199 (venetoclax) (4), but CLL still remains largely incurable due to frequent relapses and the emergence of drug resistance or intolerance (5).